Business Name: Caspr Biotech
Business Description: Caspr Biotech is a new company developing disposable CRISPR-based diagnostic devices [2].
Data/Evidence of Effectiveness: None available
Complimentary Products Needed to Perform Test: None other than the disposable test strip/device itself [4].
Setting of Care: Point-of-care, home, laboratory [2, 4]
Current Status / Clinical Development Stage / Expected Milestones: Assumed to be in very early development based on lack of information available
LOD: Information not available
Funding & Ownership : Private, seed funding status [3]. Gathered $450,000 in 3 funding rounds [3].
Business Model: Caspr Biotech is developing CRISPR-based disposable tests for disease detection (still early in development) [2]
History & Origins : Founded in 2018, focused on developing disposable CRISPR-based diagnostic devices [2, 3]
Date EUA Issued: No EUA issued
Sources: [1] https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization [2]https://caspr.bio/ [3] https://www.crunchbase.com/organization/caspr [4]https://caspr.bio/technology.html [5]https://kaloramainformation.com/point-of-care-testing-for-covid-19/
Organization: Franco Goytia (Founder) [3]
No. Tests Per Day: Disposable single use test, if considered comparable to a serology strip then >2000/day
Time to Result: Results in less than 30 minutes [4].
Test Sample Type: Assumed to be blood sample based on Caspr Biotech technology webpage [4].
Technology Overview: Point-of-care disposable test which utilizes CRIPSR to detect disease nucleic acid sequences [4]
Testing Type: CRIPSR-based nucleic acid detection, disposable point-of-care test [2, 4]
Test Name: Phantom 1.0 Dx [5]
Clinical Application & Need: Nucleic acid test [4], assumed to be qualitiative.
Age of Company: 2 years old, founded in 2018 [3]
